GSK Exercises Option to License ChemoCentryx's CCR1 Inhibitor,...

There are 1 comment on the Jan 5, 2012, Sys-Con Media story titled GSK Exercises Option to License ChemoCentryx's CCR1 Inhibitor,.... In it, Sys-Con Media reports that:

"This announcement is a key milestone for ChemoCentryx that further validates our ability to advance new medicines from drug discovery through clinical development," said , Ph.D., President and Chief Executive Officer of ChemoCentryx.A "Furthermore, the exercise fee associated with this agreement provides additional financial flexibility to our ... (more)

Join the discussion below, or Read more at Sys-Con Media.

Robson

Toronto, Canada

#1 May 6, 2012

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

ChemoCentryx Discussions

Title Updated Last By Comments
News IPO Preview: ChemoCentryx (May '12) May '12 Robson 1
News GSK licenses experimental arthritis treatment f... (May '12) May '12 Robson 1
News GSK Licenses RA Drug from ChemoCentryx (May '12) May '12 Robson 1
News GlaxoSmithKline Exercises Option to License Che... (May '12) May '12 Joan 1
News GSK obtains exclusive license to ChemoCentryx's... (May '12) May '12 Joan 1
News Drug developer ChemoCentryx has priced its IPO ... (May '12) May '12 Joan 1
News Market Report, "Diabetic Nephropathy - Pipeline... (May '12) May '12 Joan 1
More from around the web